Comments
Commented by André Will-Laudien on January 16th, 2024 | 07:15 CET
E-mobility boom 2024, when will the German vehicle market take off? BYD, Edison Lithium, VW, BMW
The last word in e-mobility has not yet been spoken. While BYD is leading the sales list worldwide, Tesla is struggling with important supplier parts and has had to halt production temporarily. German manufacturers have used the last two years to catch up on technical backlogs and are preparing to score points in the "electric world", too. Last year, buyers were offered a state environmental bonus on top, but this was cancelled before Christmas. Now, the market has to prove that it can survive with fewer subsidies. Where are the opportunities for investors?
Read
Commented by Stefan Feulner on January 16th, 2024 | 07:00 CET
Nel Asa, Altech Advanced Materials, Nordex - Now the analysts speak
Here we go again; the eagerly awaited reporting season began last week. After the major banks initially published their figures, both positive and negative surprises are likely to dominate the markets until mid-February. Several analyst firms have already expressed their forecasts and adjusted their share price targets in advance. The performance of companies in the renewable energy sector is likely to be particularly exciting. High volatility is guaranteed here.
Read
Commented by André Will-Laudien on January 15th, 2024 | 06:45 CET
Biotech: Corona is back! The doublers are lurking here: BioNTech, Evotec, Defence Therapeutics and Bayer
We had almost forgotten about Corona and the good old flu, but it is back in full swing. Governments are remaining calm and holding on to their regained liberalism. However, Spain is now resorting to drastic measures again to protect vulnerable population groups. A mask is to be compulsory again in all Spanish healthcare facilities due to the increase in respiratory diseases. Health Minister Mónica García had previously failed to convince the Spanish regions of the need to introduce compulsory masks of their own accord. In some parts of the country, hospital emergency rooms are under severe pressure due to high patient numbers. Biotech stocks are showing the first signs of recovery after the sell-off in 2023. We take a look at a few selected stocks with 100% potential.
Read
Commented by Stefan Feulner on January 15th, 2024 | 06:30 CET
Hertz, Saturn Oil + Gas, Occidental Petroleum - Clear signs of a trend reversal
Electromobility, often hailed as the future of transportation, is at the forefront of a global transport revolution. A swansong has already been sung for the traditional combustion engine. However, the fossil fuel-powered vehicle is still by far the best-selling vehicle. Issues with battery-powered vehicles are increasing. In addition to the continuing lack of refueling infrastructure, the purchase prices are simply too high without government subsidies. Additionally, higher repair costs are becoming more prevalent.
Read
Commented by Armin Schulz on January 11th, 2024 | 07:30 CET
Altech Advanced Materials, BYD, JinkoSolar - The Era of Energy Autonomy
In an era where energy not only needs to be generated but also intelligently managed, batteries and energy storage systems are increasingly taking centre stage. They are the inconspicuous heroes of the energy transition that will significantly shape our understanding of sustainability. While renewable energy from sun, wind and water is increasingly feeding into our power grid, reliable storage solutions are the key to using energy where and when it is actually needed. We look at Altech Advanced Materials, a company offering two exciting solutions for the future, and examine BYD, the top dog of electromobility alongside Tesla. Lastly, we explain why JinkoSolar can benefit from future energy storage systems.
Read
Commented by Juliane Zielonka on January 11th, 2024 | 07:15 CET
From innovative cancer therapy to menopause: How Defence Therapeutics, Bayer and NVIDIA are reshaping the medical landscape
The global prevalence of lung cancer as the second most common cancer and the challenges associated with it have led Defence Therapeutics to develop an innovative solution. Through unconventional nasal delivery, following the motto "through the nose to the lungs", the non-hormonal drug enables the precise distribution of the active ingredient. This advance could replace conventional surgical procedures for lung cancer and open up new avenues in cancer therapy. Bayer aims to generate EUR 1 billion in sales in women's health. The drug aims to alleviate the many symptoms of menopause effectively and opens up new revenue prospects for Bayer in the field of women's health. NVIDIA brings pharmaceutical research into the digital age. BioNeMo, a generative AI platform, enables research and development teams to represent drugs directly on the computer. Discover the opportunities emerging for investors now.
Read
Commented by Fabian Lorenz on January 11th, 2024 | 07:00 CET
Evotec is in the analyst check, Tui with Wanderlust, and another 100% gain for Manuka Resources?
The Evotec stock is currently not for the faint-hearted. After the resignation of the long-serving board member caused uncertainty, the biotech company was able to reassure investors with a milestone payment. Analysts are speaking out and expressing their opinions, and a real "bull" is among them. And what about Manuka Resources? At the beginning of December, news about an exciting project for battery metals caused a jump in the share price. Is it now worth getting in after the consolidation? The Tui share has also recently consolidated after a 50% gain within a few weeks. Analysts' price targets for the tourism company's shares vary widely. Hold or buy?
Read
Commented by Juliane Zielonka on January 10th, 2024 | 12:00 CET
Cardiol Therapeutics, Morphosys, BioNTech - Who will switch to the fast lane in 2024?
The life science and biotech sector has a few aces up its sleeve in 2024. Cardiol Therapeutics announces a significant clinical milestone, with over 50% of participants now enrolled in the ARCHER trial for acute myocarditis. MorphoSys, a cancer drug company, is developing an oral therapy specifically for proteins against myelofibrosis with the promising compound "pelabresib". However, analysts disagree on the share valuation. Top dog BioNTech is planning sales of EUR 3 billion in 2024, also focusing on oncology. CEO Uğur Şahin emphasizes the strategic scaling of the cancer therapy business by 2025 and initial market launches by 2026. Who will use 2024 to move into the fast lane?
Read
Commented by Fabian Lorenz on January 10th, 2024 | 07:30 CET
Bayer with a blockbuster! Vonovia weak! And how are Desert Gold shares doing?
While the DAX, Dow & Co. started the new year weakly, Bayer shares are holding up surprisingly well and can maintain the price gains from the end of 2023. The share price is being supported by positive news. A new blockbuster is waiting in the wings. Vonovia shares, on the other hand, are suffering from profit-taking, although analysts see further upside potential. Is concrete gold celebrating a comeback? And what about real gold? The price has weakened recently, but analysts believe USD 2,200 per ounce is possible, and central banks continue buying heavily. This should benefit not only the major gold producers but also low-cost explorers such as Desert Gold.
Read
Commented by Armin Schulz on January 10th, 2024 | 07:15 CET
Evotec, Defense Metals, PayPal - There is movement here. Where is it worth getting in?
In the dynamic environment of the stock market, it is often significant movements in individual shares that attract the attentive eye of investors. Volatile securities lure investors with the promise of quick profits, but they may signal more than just short-term market fluctuations. When stocks start to move and deviate from their usual trading patterns, it can indicate fundamental changes in the business environment, industry-specific developments or macroeconomic turning points. For the savvy investor, this might be the opportune moment when promising entry opportunities reveal themselves. However, caution is advised: Only those prepared to look behind the scenes and analyze the factors behind the volatility can truly profit from market movements.
Read